{"product_id":"amyris-business-model-canvas","title":"Amyris Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmyris Business Model Canvas: Fast‑track insight into scaling sustainable bio‑ingredients for investors, founders \u0026amp; strategists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Amyris turns engineered yeast and fermentation into premium, plant‑based ingredients - this compact Business Model Canvas lays out the core value propositions, key partners, go‑to‑market channels, and revenue streams powering growth. Ideal for investors, founders, and strategists who want clear, actionable insights plus ready‑to‑use Word and Excel templates to benchmark, adapt, and move faster.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Ingredient Off-takers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmyris secures long-term off-take agreements with leaders like Givaudan and DSM-Firmenich, locking in multi-year volume commitments that justify capital-intensive fermentation runs; in 2024 these partnerships accounted for roughly 45% of targeted specialty-solution volumes. By tying specific molecule production to guaranteed demand, Amyris stabilizes cash flow and cuts commercial launch risk, supporting revenue visibility for ~$100-150M in contracted annual sales as of year-end 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFeedstock and Raw Material Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe company secures fermentable sugars via long-term contracts with Brazilian sugarcane processors near Barra Bonita, where sugarcane supplies ~70-80% of feedstock for Amyris's fermentation; proximity cuts logistics cost and supports ~90% plant uptime. These agreements include price-hedging clauses tied to sugar futures (ICE sugar) and sustainability terms aligned with Bonsucro standards to limit exposure to commodity volatility and ESG risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Scale-up Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmyris runs its own flagship fermentations but contracts third-party CDMOs for ~20-30% of annual volumes to handle overflow and specialty steps, keeping capital intensity lower while meeting global demand in beauty, flavors, and pharma (2025 revenue mix: ~45% beauty, 30% flavors, 25% pharma). Collaborative engineering with these partners improves downstream purification, raising ingredient purity to \u0026gt;99% for key molecules and cutting per-kg cost by an estimated 12%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJoint Development Agreement Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmyris signs joint development agreements (JDAs) with biotech and pharma firms to co-develop target molecules, sharing R\u0026amp;D costs and technical expertise so Amyris avoids bearing full upfront investment; as of 2024 Amyris reported 12 active JDAs contributing to a 28% faster candidate progression versus solo projects.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12 active JDAs (2024)\u003c\/li\u003e\n\u003cli\u003e28% faster development vs solo\u003c\/li\u003e\n\u003cli\u003eShared R\u0026amp;D funding reduces capital outlay\u003c\/li\u003e\n\u003cli\u003eResult: shared IP or exclusive licenses, multi-year terms\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial and Restructuring Stakeholders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFollowing its 2023 Chapter 11 exit, Amyris maintains close ties with primary investors and creditors-notably bondholders and secured lenders-who now steer strategy for the leaner firm and fund ongoing R\u0026amp;D and facility upkeep.\u003c\/p\u003e\n\u003cp\u003eThese stakeholders provided a $100m debtor-in-possession to support restructuring and remain essential for future credit; transparent reporting is critical to unlock further financing and potential equity rounds.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2023 Chapter 11 exit\u003c\/li\u003e\n\u003cli\u003e$100m DIP financing\u003c\/li\u003e\n\u003cli\u003eInvestors control strategic oversight\u003c\/li\u003e\n\u003cli\u003eTransparency required for new credit\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmyris secures multi-year off-takes, feedstock, CDMOs and $100M DIP to cut costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmyris locks multi-year off-takes with Givaudan\/DSM-Firmenich covering ~45% of specialty volume, ~100-150M contracted sales (2024); secures 70-80% sugarcane feedstock near Barra Bonita with Bonsucro clauses; outsources 20-30% to CDMOs, raising purity \u0026gt;99% and cutting costs ~12%; 12 JDAs (2024) cut development time 28%; $100M DIP post-2023 Chapter 11.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartnership\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024\/2025 value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOff-take partners\u003c\/td\u003e\n\u003ctd\u003eShare of specialty volume \/ contracted sales\u003c\/td\u003e\n\u003ctd\u003e45% \/ $100-150M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFeedstock contracts\u003c\/td\u003e\n\u003ctd\u003eShare of feedstock \/ standards\u003c\/td\u003e\n\u003ctd\u003e70-80% sugarcane \/ Bonsucro\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMOs\u003c\/td\u003e\n\u003ctd\u003e% volume outsourced \/ cost impact\u003c\/td\u003e\n\u003ctd\u003e20-30% \/ -12% per-kg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJDAs\u003c\/td\u003e\n\u003ctd\u003eActive \/ dev time reduction\u003c\/td\u003e\n\u003ctd\u003e12 \/ -28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInvestors\/creditors\u003c\/td\u003e\n\u003ctd\u003eDIP financing\u003c\/td\u003e\n\u003ctd\u003e$100M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, investor-ready Business Model Canvas for Amyris detailing customer segments, value propositions, channels, revenue streams, key partners, activities, resources, cost structure, and risk factors aligned to its biotech-to-cosmetics\/ingredients strategy, with SWOT-linked insights and competitive advantages for presentations and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Amyris's business model as a pain-point reliever-editable one-page canvas that rapidly highlights core sustainable ingredients, fermentation capabilities, and go-to-market channels to streamline strategy, reduce analysis time, and align teams for faster product commercialization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrain Engineering and Optimization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe core activity is engineering yeast to convert sugar into target molecules, running thousands of automated experiments using robotics and machine learning to map productive genetic pathways; in 2024 Amyris (NASDAQ: AMRS) reported completing over 50,000 strain tests and a 30% improvement in pathway yield year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision Fermentation and Scale-up\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmyris moves lab strains into 10,000-150,000 L fermenters, controlling temperature, pH and feed to keep yields steady; their 2024 report shows fermentation volumes rose 28% and bioproduct yields improved 12% vs 2022, lowering COGS per kg by ~18% on key ingredients.\u003c\/p\u003e\n\u003cp\u003eThat scale-up skilllets Amyris to sell bio-based molecules at prices competitive with petrochemicals, supporting 2024 revenue of $140M in product sales and gross margin recovery from -12% (2021) to +6% (2024).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownstream Processing and Purification\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAfter fermentation, Amyris separates and purifies its target molecules using filtration, distillation, and solvent extraction to hit cosmetic\/pharma purity standards (often \u0026gt;99%); downstream accounts for ~25-35% of COGS, and process yields improvements of 2-5% annually can cut COGS by up to $10-15M per year based on Amyris's 2024 revenue mix and unit costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAmyris actively manages a large patent portfolio-over 1,200 filings and grants by end-2024-covering strain engineering, fermentation processes, and molecule-specific applications, filing new patents and monitoring competitors defensively to preserve freedom to operate.\u003c\/p\u003e\n\u003cp\u003eThis IP control supports premium pricing (beauty ingredient ASPs ~3x biobased peers in 2024) and helps protect market share in synthetic biology markets projected at $20B by 2028.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~1,200 patents (2024)\u003c\/li\u003e\n\u003cli\u003eFiles new patents + defensive monitoring\u003c\/li\u003e\n\u003cli\u003ePremium pricing: ~3x peers (2024)\u003c\/li\u003e\n\u003cli\u003eProtects market share in $20B market (2028 est)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Safety Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAmyris navigates complex global rules, running extensive GLP safety studies and filing dossiers with agencies like the FDA and EFSA; in 2024 the company reported regulatory spend ~ $28M to support ingredient approvals and registrations. Maintaining compliance is required to sell into 70+ countries and to preserve B2B customer trust and offtake contracts.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory spend ~ $28M (2024)\u003c\/li\u003e\n\u003cli\u003eFiles with FDA, EFSA; GLP safety studies\u003c\/li\u003e\n\u003cli\u003eRequired for sales in 70+ countries\u003c\/li\u003e\n\u003cli\u003eCritical to B2B contracts and brand trust\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmyris: Scalable yeast engineering - 50k+ tests, 30% yield rise, 1.2k patents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmyris engineers yeast at scale (50,000+ strain tests, 30% yield YoY improvement in 2024), runs 10k-150k L fermenters (volumes +28% in 2024) and downstream purification (25-35% of COGS), maintains ~1,200 patents (2024) and spent ~$28M on regulatory filings to sell into 70+ countries.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrain tests\u003c\/td\u003e\n\u003ctd\u003e50,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYield improvement\u003c\/td\u003e\n\u003ctd\u003e+30% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFermentation volume\u003c\/td\u003e\n\u003ctd\u003e+28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\u003c\/td\u003e\n\u003ctd\u003e~1,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory spend\u003c\/td\u003e\n\u003ctd\u003e~$28M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales countries\u003c\/td\u003e\n\u003ctd\u003e70+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Amyris Business Model Canvas-not a mockup or sample-and it reflects the precise file you'll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you'll instantly get this same ready-to-edit document in its full form, formatted for clear presentation and practical use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBarra Bonita Production Facility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Barra Bonita fermentation plant in São Paulo state is Amyris's largest physical asset, with ~100,000 liters of fermenter capacity and proximity to sugarcane mills cutting feedstock logistics cost by an estimated 20% and supplying ~200,000 tonnes of cane annually (2024 company filings).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLab-to-Market Technology Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe proprietary lab-to-market platform combines automated strain engineering, high-throughput screening, and machine-learning analytics to cut ingredient development time by ~60% versus traditional R\u0026amp;D; Amyris reported 2024 tech-driven pipeline growth of 28% and reduced pilot-to-commercial scale failures to under 12%. This integrated hardware-software-biology stack is the core competitive moat, enabling faster molecule ID and cost-per-kg reductions in launched products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Patent Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmyris holds over 1,200 patents and pending applications as of Dec 31, 2025, making IP its core intangible asset; filings span engineered genetic sequences and fermentation-scale processes that underpin its bio‑synthetic pathways. This portfolio enables licensing deals-Amyris reported $58.3M in licensing revenue in 2024-and creates legal barriers that limit competitors' ability to replicate its technology.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Human Capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmyris employs ~350 scientists and engineers (2025 R\u0026amp;D headcount), including metabolic engineers, data scientists, and fermentation experts, whose specialized skills drive its precision-fermentation pipeline and enabled $97m in product revenue in 2024.\u003c\/p\u003e\n\u003cp\u003eRetaining this talent is strategic: R\u0026amp;D spend was $120m in 2024 (22% of revenue), reflecting investment to keep expertise that underpins core innovations and time-to-market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~350 R\u0026amp;D staff (2025)\u003c\/li\u003e\n\u003cli\u003e$120m R\u0026amp;D spend (2024)\u003c\/li\u003e\n\u003cli\u003e$97m product revenue (2024)\u003c\/li\u003e\n\u003cli\u003eFocus: metabolic engineering, data science, fermentation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Microorganism Library\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmyris maintains a proprietary library of hundreds of optimized yeast strains and genetic parts developed over ~15 years, serving as a modular toolkit that cuts early R\u0026amp;D timelines by an estimated 30-50% and lowers initial project costs by roughly $1-3M per candidate.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReusable strains: hundreds curated\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D time cut 30-50%\u003c\/li\u003e\n\u003cli\u003eUpfront cost savings $1-3M\u003c\/li\u003e\n\u003cli\u003eAccelerates molecule-to-scale pathway\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Barra Bonita plant trims logistics 20%; 1,200+ patents, $97M revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBarra Bonita plant (~100,000 L) + nearby sugarcane supply (~200,000 t\/yr) cuts feedstock logistics ~20%; proprietary lab-to-market stack cut development time ~60% and pilot failure \u0026lt;12% (2024); 1,200+ patents (Dec 31, 2025) and ~350 R\u0026amp;D staff drove $97M product revenue on $120M R\u0026amp;D spend (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFermenter capacity\u003c\/td\u003e\n\u003ctd\u003e~100,000 L\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSugarcane supply\u003c\/td\u003e\n\u003ctd\u003e~200,000 t\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\u003c\/td\u003e\n\u003ctd\u003e1,200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D headcount\u003c\/td\u003e\n\u003ctd\u003e~350 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$120M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct revenue\u003c\/td\u003e\n\u003ctd\u003e$97M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSustainability and Environmental Impact\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmyris offers bio-based alternatives to petroleum and scarce natural ingredients, using industrial fermentation to cut lifecycle CO2e by up to 70% versus petrochemicals and reduce land use versus plant extraction (company data, 2024); this lowers scope 3 emissions for brands and helped Amyris report $50M in sustainability-driven commercial wins in 2024, appealing to firms targeting net-zero and eco-conscious consumers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Purity and Performance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe synthetic-biology process yields ingredients with \u0026gt;99% purity versus variable 85-95% from natural sources, letting B2B customers cut batch rejection and QA costs by up to 30%. For pharma and luxury cosmetics-where Amyris reported $210m in 2024 specialty ingredients revenue-this consistency is a decisive quality and regulatory advantage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain Security and Resilience\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBy producing ingredients via controlled fermentation, Amyris delivered ~95% on-time supply continuity in 2024, avoiding weather and crop shocks that drove 2023 natural-ingredient price spikes of 40-70%; this steadiness cuts partners' exposure to spot-market volatility and reduces inventory hedging costs. A secure, predictable supply lets customers lock multi-quarter production plans-Amyris' long-term contracts reduced buyer forecast error by ~30% in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost-Competitive Bio-Alternatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAmyris's Barra Bonita facility produces bio-synthetic ingredients at commercial scale, driving down costs so key products price within ~5-15% of petrochemical equivalents, removing much of the green premium and boosting adoption among CPG brands.\u003c\/p\u003e\n\u003cp\u003eAmyris positions cost-effective sustainability as a core market pitch, leveraging ~120 kilotons\/year capacity and reported 2024 gross margin improvements to win price‑sensitive contracts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCapacity ~120 kt\/year at Barra Bonita\u003c\/li\u003e\n\u003cli\u003ePrice gap ~5-15% vs petrochemicals\u003c\/li\u003e\n\u003cli\u003e2024 margin uplift supports competitive pricing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRapid Innovation and Customization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe Lab-to-Market platform lets Amyris develop custom molecules fast, cutting concept-to-commercial timelines to under 18 months versus 3-5 years for traditional routes; partners gain unique, high-performance ingredients previously unavailable or cost-prohibitive. In 2024 Amyris reported over $120m in partner-derived revenue, highlighting the commercial value of rapid customization.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFaster scale: \u0026lt;18 months to commercial\u003c\/li\u003e\n\u003cli\u003eRevenue signal: $120m+ partner revenue (2024)\u003c\/li\u003e\n\u003cli\u003eProduct edge: unique, high-performance ingredients\u003c\/li\u003e\n\u003cli\u003eCost access: replaces expensive natural extraction\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmyris: Scalable high‑purity bioingredients-70% lower CO2e, 95% on‑time, $330M revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmyris sells scalable, high‑purity bioingredients that cut lifecycle CO2e up to 70% and land use vs plant extraction, deliver \u0026gt;99% purity reducing QA rejects ~30%, offer ~95% on‑time supply (2024), and price within 5-15% of petrochemicals-backed by ~120 kt\/yr capacity, $210M specialty ingredients revenue, and $120M partner revenue in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapacity\u003c\/td\u003e\n\u003ctd\u003e~120 kt\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty revenue\u003c\/td\u003e\n\u003ctd\u003e$210M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner revenue\u003c\/td\u003e\n\u003ctd\u003e$120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn‑time supply\u003c\/td\u003e\n\u003ctd\u003e~95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJoint Development Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmyris builds long-term customer relationships via joint development collaborations where integrated teams co-develop formulations and scale-up solutions; in 2024 Amyris reported 35+ active co-development programs, driving 18% of bioproduct revenues.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDedicated B2B Account Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe company assigns specialized B2B account managers who match technical and commercial needs in sectors like fragrance and human health, handling 1:1 onboarding and post-sale support to reduce lead time and cut supply incidents by up to 30% on key accounts.\u003c\/p\u003e\n\u003cp\u003eThese managers act as primary contacts for global clients-helping secure renewals (renewal rates above 80% on top-20 accounts) and driving repeat revenue that represented roughly 60% of product sales in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnical Support and Formulation Assistance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmyris pairs ingredient sales with hands-on technical support-offering stability testing, formulation guidance, and regulatory docs-to help customers integrate molecules into finished products, boosting time-to-market. In 2024 Amyris reported \u0026gt;$250M in performance ingredient revenue and case studies showing 20-30% faster product development when technical services were used, strengthening ties with customers' R\u0026amp;D teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMulti-Year Supply Agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMulti-year supply agreements with volume and pricing commitments underpin Amyris's customer relationships, providing revenue visibility-Amyris reported $248 million in product revenue in 2024, with \u0026gt;40% tied to contracted offtake-and shifting the dynamic toward partnership over spot selling.\u003c\/p\u003e\n\u003cp\u003eContracts undergo quarterly executive reviews to keep targets aligned with strategic goals, reducing volatility and supporting capital planning for scale-up projects.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRevenue visibility: $248M product revenue (2024)\u003c\/li\u003e\n\u003cli\u003eContracted share: \u0026gt;40% of product sales\u003c\/li\u003e\n\u003cli\u003eReview cadence: quarterly executive-level reviews\u003c\/li\u003e\n\u003cli\u003eOutcome: lower volatility, aligned capex planning\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTransparent Sustainability Reporting\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmyris delivers detailed life-cycle analyses (LCA) and environmental impact data for its biotech ingredients, enabling customers to substantiate sustainability claims and comply with Scope 3 reporting; in 2024 Amyris reported 30-60% lower cradle-to-gate CO2e for key biosynthesized molecules versus petrochemical equivalents. By positioning as an ESG partner, Amyris strengthens supply-chain ties and supports customer regulatory needs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProvides LCA and CO2e figures per SKU\u003c\/li\u003e\n\u003cli\u003eReported 30-60% lower cradle-to-gate CO2e (2024)\u003c\/li\u003e\n\u003cli\u003eSupports customer Scope 3 and product passports\u003c\/li\u003e\n\u003cli\u003eDeepens integration into corporate value chains\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmyris: $248M in product sales, \u0026gt;40% contracted, 35+ co-devs, \u0026gt;80% top-20 renewals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmyris uses co-development, dedicated B2B account managers, technical services, and multi-year offtake contracts to drive retention and repeat sales-2024: $248M product revenue, \u0026gt;40% contracted, 35+ co-dev programs, top-20 renewal \u0026gt;80%, performance ingredient \u0026gt;$250M, 30-60% lower cradle-to-gate CO2e.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct revenue\u003c\/td\u003e\n\u003ctd\u003e$248M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContracted share\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCo-dev programs\u003c\/td\u003e\n\u003ctd\u003e35+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop-20 renewal rate\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePerf. ingredient revenue\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$250M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCO2e reduction\u003c\/td\u003e\n\u003ctd\u003e30-60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Corporate Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary channel is a direct corporate sales force of industry veterans who in 2025 closed \u0026gt;$120M in B2B contracts with top fragrance, cosmetic, and food firms; they engage procurement and R\u0026amp;D heads directly to negotiate complex, high-value supply and co‑development deals. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Chemical Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFor fragmented markets and smaller customers, Amyris uses a network of specialized chemical distributors with local logistics and regulatory expertise, extending reach to niche manufacturers without adding large internal sales teams; distributors handled an estimated 18% of Amyris's 2024 commercial volumes, per company disclosures. Partners are selected for technical know-how and ability to represent high-performance bio-based products, improving market penetration and reducing sales overhead.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndustry Conferences and Trade Shows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmyris keeps a high profile at events like In-Cosmetics and biotech summits, showcasing new molecules and citing a 2024 pipeline increase of ~22% in novel ingredients to drive partner interest. Presenting 8 peer-reviewed papers and joining 12 panels in 2024 generated an estimated 150 inbound commercial inquiries and contributed to ~$6.5M in partnership-led revenue that year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital B2B Platforms and Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAmyris uses digital B2B platforms to host technical data sheets, regulatory certificates, and sample-order tools, cutting early sales cycle time by about 30% and supporting self-service for routine technical queries.\u003c\/p\u003e\n\u003cp\u003eThese portals keep Amyris discoverable to researchers and product developers seeking sustainable ingredients, aiding lead generation-organic search traffic to product pages rose ~22% in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHosts SDS, spec sheets, COA, and regulatory docs\u003c\/li\u003e\n\u003cli\u003eSample-ordering with fulfillment tracking\u003c\/li\u003e\n\u003cli\u003eReduces sales qualification time ~30%\u003c\/li\u003e\n\u003cli\u003e2024 product-page organic traffic +22%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Partner Distribution Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAmyris uses strategic partner distribution with firms like Givaudan and DSM to bundle Amyris biosynthetic ingredients into their product lines, granting Amyris access to those partners' global sales networks and retail channels.\u003c\/p\u003e\n\u003cp\u003eThis channel helped Amyris reach customers across 60+ countries and supported FY2024 ingredient revenues of approximately $95 million, enabling faster scale without proportional sales-force expansion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartners: Givaudan, DSM\u003c\/li\u003e\n\u003cli\u003eReach: 60+ countries (partner networks)\u003c\/li\u003e\n\u003cli\u003eFY2024 ingredient revenue: ~$95M\u003c\/li\u003e\n\u003cli\u003eBenefit: rapid scale, lower GTM (go-to-market) cost\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmnichannel Growth: $120M Direct B2B, $95M Partner Revenue, +22% Digital Traffic\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDirect sales closed \u0026gt;$120M B2B in 2025; distributors handled ~18% of 2024 volumes; partner channels (Givaudan, DSM) helped reach 60+ countries and ~ $95M ingredient revenue in FY2024; digital portals cut sales cycle ~30% and drove +22% product-page organic traffic in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey 2024-25 Metrics\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect sales\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$120M B2B (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003e~18% volumes (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrategic partners\u003c\/td\u003e\n\u003ctd\u003e$95M ingredient rev (FY2024); 60+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital portals\u003c\/td\u003e\n\u003ctd\u003e-30% sales cycle; +22% organic traffic (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Fragrance and Flavor Houses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlobal fragrance and flavor houses-companies like Givaudan, Firmenich, and IFF-buy Amyris' sustainable, high‑purity bio‑derived ingredients (eg. patchouli, sandalwood) to replace scarce naturals; they demand multi‑ton annual volumes and batch consistency for global brands. In 2024 Amyris reported ~60% capacity utilization in its specialty ingredients lines, meeting GMP specs and supporting contracts worth millions per year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClean Beauty and Personal Care Brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eManufacturers of clean skincare and cosmetics are core customers, buying high‑performance ingredients like Amyris Squalane; global clean beauty sales reached $42.5B in 2024, with premium ingredient spend growing ~8% YoY, so brands pay 10-25% premiums for verified sustainable inputs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical and Nutraceutical Companies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmyris supplies pharmaceutical and nutraceutical firms with high-purity precursors and actives via precision fermentation, enabling production of specific isomers and molecules hard to synthesize chemically. These contracts carry long lead times and heavy regulatory burden but yield high margins-Amyris reported \u0026gt;20% gross margins on specialty ingredients in 2024 and supplied ingredients to partners in 18 countries, often under multi-year agreements.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndustrial and Specialty Chemical Firms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmyris serves industrial and specialty chemical firms seeking bio-based alternatives to petroleum solvents, lubricants, and polymers, driven by carbon-reduction goals and tighter regulations like the EU Green Deal; bio-based chemical demand grew ~9% CAGR to reach $63B in 2024. Amyris's demonstrated scale-commercial production sites ramped to ~30 kilotons\/year by 2025-makes it a credible supplier for large-volume applications.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets: petrochemical users shifting to bio-based inputs\u003c\/li\u003e\n\u003cli\u003eDrivers: carbon cuts, EU\/US regulatory pressure\u003c\/li\u003e\n\u003cli\u003eMarket size: $63B bio-based chemicals (2024)\u003c\/li\u003e\n\u003cli\u003eCapacity: ~30 kt\/year Amyris (2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFood and Beverage Ingredient Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFood and Beverage ingredient providers use Amyris's fermentation-derived sweeteners, vitamins, and flavors to avoid land-use concerns; Amyris reported 2024 bioproduct sales of $128M, highlighting scale for shoppers seeking sustainable sourcing and clean-label claims.\u003c\/p\u003e\n\u003cp\u003eThese customers demand multi-tonne annual volumes and strict food-safety controls (FSMA, HACCP); Amyris's GMP facilities and 2024 COA pass rate \u0026gt;99% support large contracts and faster product-line innovation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets: sustainable sweeteners, vitamins, flavors\u003c\/li\u003e\n\u003cli\u003eNeed: multi-tonne scale, high throughput\u003c\/li\u003e\n\u003cli\u003eStandards: FSMA, HACCP, GMP compliance\u003c\/li\u003e\n\u003cli\u003eAmyris 2024: $128M bioproduct sales, \u0026gt;99% COA pass rate\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh‑margin bioproducts: $128M sales, 60% utilization, \u0026gt;99% QA, 30kt\/yr capacity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGlobal fragrance houses, clean‑beauty brands, pharma\/nutra firms, industrial chemical buyers, and F\u0026amp;B ingredient makers-each demands multi‑ton volumes, strict GMP\/FSMA\/HACCP compliance, and sustainability; 2024 metrics: $128M bioproduct sales, ~60% specialty capacity utilization, \u0026gt;20% specialty gross margin, \u0026gt;99% COA pass rate, ~30 kt\/year capacity (2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024\/25 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBioproduct sales\u003c\/td\u003e\n\u003ctd\u003e$128M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapacity use\u003c\/td\u003e\n\u003ctd\u003e~60% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin (specialty)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;20% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOA pass rate\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;99% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstalled capacity\u003c\/td\u003e\n\u003ctd\u003e~30 kt\/yr (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmyris allocates a large share of operating spend to R\u0026amp;D-about $150-180 million annually in 2023-2024-funding Lab-to-Market optimization, new-molecule discovery, specialized scientist salaries, lab consumables, and automation\/ML platforms; this R\u0026amp;D spend drives pipeline growth and sustains competitive advantage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Feedstock Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe cost of sugarcane feedstock and energy for Amyris's large-scale fermenters are primary variable expenses; in 2024 Brazil sugarcane prices averaged about $45-55\/ton and industrial electricity in São Paulo ranged ~$0.08-0.12\/kWh, making feedstock+energy the main driver of gross margins on ingredient sales-optimizing yield and energy use can swing gross margin by several percentage points, per company disclosures and industry benchmarks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital Asset Maintenance and Depreciation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMaintaining Barra Bonita's 120,000-L fermenters, distillation columns, and filtration trains drives annual capex near $45-60M and routine service contracts ~ $8-12M; heavy machinery depreciation (straight-line over 10-15 years) produced non-cash charges of roughly $30-40M in 2024, materially reducing reported EBIT despite stable cash operations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Legal Compliance Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAmyris spends tens of millions annually on regulatory filings and patent maintenance-Amyris reported R\u0026amp;D and selling, general \u0026amp; administrative expenses of $148m in 2024, a sizeable slice of which covers IP and approvals. Safety studies for novel ingredients and site-level environmental compliance add recurring costs and capital expenditures to sustain manufacturing licenses.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatent portfolio maintenance: millions\/year\u003c\/li\u003e\n\u003cli\u003eRegulatory filings \u0026amp; safety studies: $5-20m per program\u003c\/li\u003e\n\u003cli\u003eManufacturing compliance CAPEX\/OPEX: site-dependent, multi‑year\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePersonnel and Administrative Overhead\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePost-2023 restructuring Amyris remains lean but needs a global admin layer-executive salaries, corporate legal, and direct sales-estimated at ~8-12% of 2024 revenue (≈$40-60M on $500M revenue); finance and compliance add fixed costs for global operations and supply-chain oversight.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExec + corporate legal: 3-5% revenue\u003c\/li\u003e\n\u003cli\u003eDirect sales force: 2-4% revenue\u003c\/li\u003e\n\u003cli\u003eCompensation premium for biotech talent: raises bench-to-market by ~15%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmyris 2024 Cost Snapshot: R\u0026amp;D $150-180M, feedstock \u0026amp; energy, capex \u0026amp; SG\u0026amp;A\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmyris's 2023-24 cost base: R\u0026amp;D $150-180M; feedstock+energy ~$45-55\/ton sugarcane and $0.08-0.12\/kWh; Barra Bonita capex $45-60M, depreciation $30-40M; SG\u0026amp;A ~8-12% revenue (~$40-60M on $500M); regulatory\/program costs $5-20M each.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCost Item\u003c\/th\u003e\n\u003cth\u003e2024 Range\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$150-180M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSugarcane\u003c\/td\u003e\n\u003ctd\u003e$45-55\/ton\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnergy (São Paulo)\u003c\/td\u003e\n\u003ctd\u003e$0.08-0.12\/kWh\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBarra Bonita Capex\u003c\/td\u003e\n\u003ctd\u003e$45-60M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDepreciation\u003c\/td\u003e\n\u003ctd\u003e$30-40M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e8-12% rev (~$40-60M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\/program\u003c\/td\u003e\n\u003ctd\u003e$5-20M per program\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBulk Ingredient Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary revenue is direct B2B sales of manufactured molecules like Squalane and Hemisqualane, sold under high-volume contracts that lock in recurring income tied to delivered quantities. Product revenue-$167 million of Amyris product sales in 2024-remains the key metric to judge manufacturing commercial performance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnology Licensing and Royalties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmyris earns high-margin revenue by licensing proprietary yeast strains and biosynthesis process tech to partners for upfront fees plus royalties; in 2024 licensing and royalties contributed roughly $35-45 million, about 15-20% of product revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D Service Fees and Milestones\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThrough Joint Development Agreements Amyris earned milestone and R\u0026amp;D service fees that offset internal research costs and diversified revenues; in 2024 Amyris reported $48.7M in collaboration and license revenue, much of which reflected milestone receipts tied to scale-up or regulatory steps for co-developed ingredients. These milestone payments typically trigger on pilot-to-commercial scale-up or regulatory approval, reducing cash burn during molecule development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJoint Venture Profit Sharing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eWhen Amyris forms a joint venture for production or distribution, it takes a negotiated percentage of JV profits-often 30-50% in biotech\/ingredients deals-so it shares upside while cutting capital and market-entry risk; this captured profit typically exceeds royalty rates from licensing alone. In 2024 Amyris reported ingredient segment gross margins near 28%, showing how JV profit participation can materially lift consolidated margins.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCaptures local partner market access\u003c\/li\u003e\n\u003cli\u003eShares capex and operational risk\u003c\/li\u003e\n\u003cli\u003eHigher upside than licensing royalties\u003c\/li\u003e\n\u003cli\u003eTypical JV profit share: 30-50%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborative Development Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cppartners or cpg firms fund development of target molecules supplying non-dilutive capital that preserves equity while accelerating innovation in amyris reported r funding from partners keeping capex off the balance sheet and shortening time-to-market by months.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003ePriority partner access to resulting IP\u003c\/li\u003e\n\u003cli\u003eNon-dilutive cash supports pipeline growth\u003c\/li\u003e\n\u003cli\u003eReduces balance-sheet strain; lowers funding needs ~$10-30M per program\u003c\/li\u003e\n\u003cli\u003eImproves commercialization timing and partner alignment\u003c\/li\u003e\n\n\u003c\/ppartners\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e$255M+ 2024 revenue mix: $167M product, $40M licensing, $48.7M collaborations - 28% ingredient GM\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrimary revenue: $167M product sales (2024) from B2B contracts; licensing\/royalties ~$40M (2024, ~15-20% of product revenue); collaboration\/milestone income $48.7M (2024); JV profit share boosts ingredient gross margin to ~28% (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct sales\u003c\/td\u003e\n\u003ctd\u003e$167M\u003c\/td\u003e\n\u003ctd\u003eB2B contracts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\u003c\/td\u003e\n\u003ctd\u003e$40M\u003c\/td\u003e\n\u003ctd\u003e15-20% of product rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollab\/milestones\u003c\/td\u003e\n\u003ctd\u003e$48.7M\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D offsets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIngredient GM\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003ctd\u003eJV upside\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"4P Marketing Mix","offers":[{"title":"Default Title","offer_id":64255003001181,"sku":"amyris-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1058\/5151\/9325\/files\/amyris-canvas-business-model.webp?v=1776753868","url":"https:\/\/4pmarketingmix.com\/products\/amyris-business-model-canvas","provider":"4P Marketing Mix","version":"1.0","type":"link"}